1.Bioreactor Conditioning of Valve Scaffolds Seeded Internally with Adult Stem Cells.
Allison KENNAMER ; Leslie SIERAD ; Richard PASCAL ; Nicholas RIERSON ; Christopher ALBERS ; Marius HARPA ; Ovidiu COTOI ; Lucian HARCEAGA ; Peter OLAH ; Preda TEREZIA ; Agneta SIMIONESCU ; Dan SIMIONESCU
Tissue Engineering and Regenerative Medicine 2016;13(5):507-515
The goal of this study was to test the hypothesis that stem cells, as a response to valve-specific extracellular matrix “niches” and mechanical stimuli, would differentiate into valvular interstitial cells (VICs). Porcine aortic root scaffolds were prepared by decellularization. After verifying that roots exhibited adequate hemodynamics in vitro, we seeded human adipose-derived stem cells (hADSCs) within the interstitium of the cusps and subjected the valves to in vitro pulsatile bioreactor testing in pulmonary pressures and flow conditions. As controls we incubated cell-seeded valves in a rotator device which allowed fluid to flow through the valves ensuring gas and nutrient exchange without subjecting the cusps to significant stress. After 24 days of conditioning, valves were analyzed for cell phenotype using immunohistochemistry for vimentin, alpha-smooth muscle cell actin (SMA) and prolyl-hydroxylase (PHA). Fresh native valves were used as immunohistochemistry controls. Analysis of bioreactor-conditioned valves showed that almost all seeded cells had died and large islands of cell debris were found within each cusp. Remnants of cells were positive for vimentin. Cell seeded controls, which were only rotated slowly to ensure gas and nutrient exchange, maintained about 50% of cells alive; these cells were positive for vimentin and negative for alpha-SMA and PHA, similar to native VICs. These results highlight for the first time the extreme vulnerability of hADSCs to valve-specific mechanical forces and also suggest that careful, progressive mechanical adaptation to valve-specific forces might encourage stem cell differentiation towards the VIC phenotype.
Actins
;
Adult Stem Cells*
;
Adult*
;
Bioreactors*
;
Extracellular Matrix
;
Heart Valves
;
Hemodynamics
;
Humans
;
Immunohistochemistry
;
In Vitro Techniques
;
Islands
;
Muscle Cells
;
Phenotype
;
Stem Cells
;
Vimentin
2.Thrombectomy in Stroke Patients With Low Alberta Stroke Program Early Computed Tomography Score: Is Modified Thrombolysis in Cerebral Infarction (mTICI) 2c/3 Superior to mTICI 2b?
Sameh Samir ELAWADY ; Brian Fabian SAWAY ; Hidetoshi MATSUKAWA ; Kazutaka UCHIDA ; Steven LIN ; Ilko MAIER ; Pascal JABBOUR ; Joon-Tae KIM ; Stacey Quintero WOLFE ; Ansaar RAI ; Robert M. STARKE ; Marios-Nikos PSYCHOGIOS ; Edgar A SAMANIEGO ; Adam ARTHUR ; Shinichi YOSHIMURA ; Hugo CUELLAR ; Jonathan A. GROSSBERG ; Ali ALAWIEH ; Daniele G. ROMANO ; Omar TANWEER ; Justin MASCITELLI ; Isabel FRAGATA ; Adam POLIFKA ; Joshua OSBUN ; Roberto CROSA ; Charles MATOUK ; Min S. PARK ; Michael R. LEVITT ; Waleed BRINJIKJI ; Mark MOSS ; Travis DUMONT ; Richard WILLIAMSON JR. ; Pedro NAVIA ; Peter KAN ; Reade De LEACY ; Shakeel CHOWDHRY ; Mohamad EZZELDIN ; Alejandro M. SPIOTTA ; Sami Al KASAB ;
Journal of Stroke 2024;26(1):95-103
Background:
and Purpose Outcomes following mechanical thrombectomy (MT) are strongly correlated with successful recanalization, traditionally defined as modified Thrombolysis in Cerebral Infarction (mTICI) ≥2b. This retrospective cohort study aimed to compare the outcomes of patients with low Alberta Stroke Program Early Computed Tomography Score (ASPECTS; 2–5) who achieved mTICI 2b versus those who achieved mTICI 2c/3 after MT.
Methods:
This study utilized data from the Stroke Thrombectomy and Aneurysm Registry (STAR), which combined databases from 32 thrombectomy-capable stroke centers between 2013 and 2023. The study included only patients with low ASPECTS who achieved mTICI 2b, 2c, or 3 after MT for internal carotid artery or middle cerebral artery (M1) stroke.
Results:
Of the 10,229 patients who underwent MT, 234 met the inclusion criteria. Of those, 98 (41.9%) achieved mTICI 2b, and 136 (58.1%) achieved mTICI 2c/3. There were no significant differences in baseline characteristics between the two groups. The 90-day favorable outcome (modified Rankin Scale score: 0–3) was significantly better in the mTICI 2c/3 group than in the mTICI 2b group (adjusted odds ratio 2.35; 95% confidence interval [CI] 1.18–4.81; P=0.02). Binomial logistic regression revealed that achieving mTICI 2c/3 was significantly associated with higher odds of a favorable 90-day outcome (odds ratio 2.14; 95% CI 1.07–4.41; P=0.04).
Conclusion
In patients with low ASPECTS, achieving an mTICI 2c/3 score after MT is associated with a more favorable 90-day outcome. These findings suggest that mTICI 2c/3 is a better target for MT than mTICI 2b in patients with low ASPECTS.